Protara Therapeutics, Inc. (TARA) — 10-Q Filings

10-Q Filings (5)

• Protara's Q3 Loss Widens Amid Soaring R&D Costs, Cash Drains — Nov 10, 2025 Risk: high
  Protara Therapeutics, Inc. (TARA) reported a net loss of $13.258 million for the three months ended September 30, 2025, an increase from the $11.219 million net
• Protara Posts $7.5M Loss, Pushes TARA-002 Ahead — Aug 11, 2025 Risk: high
  Protara Therapeutics, Inc. (TARA) filed its 10-Q for the quarter ended June 30, 2025, indicating no revenue generation, consistent with its pre-commercial stage
• Protara Therapeutics Files Q1 2025 10-Q Report — May 8, 2025 Risk: low
  Protara Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended March 31, 2025. The company, formerly known as ArTara Therapeutics, Inc.
• Protara Therapeutics Files Q3 2024 10-Q — Nov 12, 2024 Risk: medium
  Protara Therapeutics, Inc. filed its 10-Q for the quarterly period ended September 30, 2024. The company, formerly known as ArTara Therapeutics, Inc. and PROTEO
• Protara Therapeutics, Inc. Files 10-Q for Period Ended March 31, 2024 — May 2, 2024 Risk: low
  Protara Therapeutics, Inc. (TARA) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Protara Therapeutics, Inc. filed a 10-Q report for the quarterly

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX